X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Furoscix (furosemide injection) is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Furoscix® (furosemide) primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
FUROSCIX® (furosemide injection) is a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2022
Details:
FUROSCIX® (furosemide injection) is a drug product indicated for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II/III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brand Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
scPharmaceuticals plans to use funds, together with cash on-hand, to repay indebtedness under its existing loan and security agreement and to execute on the launch of FUROSCIX (furosemide), which received marketing approval from the U.S. FDA.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 10, 2022
Details:
FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for treatment of congestion,demonstrated 99.6% bioavailability and 8-hour urine output of 2.7 L which was similar to subjects receiving intravenous furosemide.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
Subject randomized to FUROSCIX (furosemide 80 mg/10 mL for subcutaneous administration), had a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to “treatment as usual” at day 30.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
FUROSCIX (furosemide), a proprietary formulation of furosemide that is designed to be administered by subcutaneous infusion via a wearable, pre-programmed on-body, drug delivery system.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
